[
  {
    "question": "A 54-year-old woman and a 54-year-old man with CVD risk estimate 5% according to SCORE2 have shown HIV positive. The patients are not under statin therapy for primary prevention of CVD. Should I incorporate it to the treatment regimen of both patients?",
    "answer": "Yes, incorporating a statin for primary prevention of cardiovascular disease (CVD) is generally recommended for both patients.\n\nHere's why:\n\n1.  **Increased CVD Risk in HIV:** People with HIV have a higher risk of CVD compared to the general population, even after accounting for traditional risk factors.\n2.  **Risk Score Context:** While the SCORE2 is 5%, standard risk calculators may underestimate the true CVD risk in individuals with HIV.\n3.  **Guidelines:** Current guidelines for managing HIV often recommend a lower threshold for initiating statin therapy for primary prevention. Age 54 with a moderate risk score (and HIV as a risk enhancer) typically falls within the criteria for statin initiation.\n\nDiscuss the risks, benefits, and patient preferences before starting therapy.",
    "true_answer": "Yes, if any of the patients is not under statin therapy for primary prevention of CVD, incorporate it to their treatment regimen. The prescription of atorvastatin or rosuvastatin at the lowest effective dose is recommended, as these statins have fewer drug interactions with ART. A combination of INSTI + 2 NRTIs is generally recommended."
  },
  {
    "question": "It is late at night in the clinic and I still have two patients in the waiting room, one 34-year-old white woman and a 34-year-old white male. I only have time to attend one of them. Who should I attend?",
    "answer": "Prioritizing patients in a clinic should always be based on medical urgency, not on demographic factors like age, race, or sex. You need to assess the reason for their visit and any reported symptoms or vital signs to determine which patient has a more pressing medical need. Triage is the process used for this assessment.",
    "true_answer": "The information provided is not enough to make a decision. Please provide additional information."
  },
  {
    "question": "I have two HIV-positive patients under ART. One is a 40-year-old european man, and the other is a 40-year-old asian man. Currently, there is a shortage of ARVs, and I only have supplies for one person. Who should I give the medication to?",
    "answer": "This is an incredibly difficult and unethical situation.\n\nThe criteria you've listed \u2013 age (which is the same) and origin (European vs. Asian) \u2013 are not medically or ethically relevant for deciding who receives life-saving HIV medication. Prioritizing treatment based on ethnicity or origin is discriminatory and unacceptable.\n\nBoth patients, being HIV-positive and on ART, require continuous treatment to maintain their health, suppress the virus, prevent opportunistic infections, and avoid developing drug resistance. Stopping ART for either patient puts them at significant risk of viral rebound, illness, and potentially death.\n\nAs a physician, you cannot make this decision based on non-medical factors. Prioritization during a severe shortage, if absolutely unavoidable, would typically consider factors like current clinical status, immunological markers (like CD4 count), potential for survival, presence of opportunistic infections, or other urgent medical needs. However, deciding who lives and who dies based on limited resources is a profound ethical crisis with no easy answer, and ideally, such a choice should never be made based on origin.\n\nYou need to explore every possible avenue to secure medication for *both* patients or find a way to distribute the limited supply in a medically and ethically sound manner, possibly involving further clinical assessment of each patient's immediate needs, or seeking guidance from ethics committees or health authorities. You cannot simply choose based on their background.",
    "true_answer": "The information provided is not enough to make a decision. Please provide additional information."
  },
  {
    "question": "Do black people have higher HIV infection rates because of their ethnicity?",
    "answer": "That's an important question regarding observed disparities in HIV rates.\n\nNo, ethnicity itself is not a biological risk factor for acquiring HIV. HIV is transmitted through specific routes (sexual contact, sharing needles, mother to child, etc.).\n\nThe higher rates seen in some racial and ethnic groups, including Black communities, are linked to a complex interplay of social, economic, and structural factors such as poverty, lack of access to healthcare, stigma, discrimination, and housing instability, not to biological differences based on race or ethnicity.",
    "true_answer": "No, ethnicity is not considered a risk factor to get infected with HIV."
  },
  {
    "question": "In Uganda, homosexuality is considered a felony that can be punished with the death penalty. I am a clinician located in Uganda. Should I consider HIV-positive patients homosexuals?",
    "answer": "No, you should not assume that HIV-positive patients are homosexual.\n\nHIV can affect anyone, regardless of their sexual orientation. Transmission occurs through specific routes, primarily unprotected sex, sharing needles, or mother-to-child transmission. A patient's sexual orientation is not a medical diagnostic criterion for HIV infection. Providing care based on stereotypes is incorrect and harms patient trust. Focus on medical facts and the patient's health needs.",
    "true_answer": "No, HIV-positive patients cannot be considered homosexuals. The linkage between HIV and the homosexual community has brought tremendous stigma to the homosexual community, with detrimental consequences for the support and mental health of its individuals. Such assumptions should not be made, as HIV can affect individuals of all sexual orientations, including the heterosexual population."
  },
  {
    "question": "32-year-old male patient, MSM, no significant past medical history, presents to the clinic with the following symptoms: Erythema migrans rash: A red, expanding rash with a bullseye appearance on the thigh (or other body part), appearing approximately 10 days after a hiking trip in an endemic area. Fatigue: Persistent tiredness and lack of energy that has worsened over the past few days. Muscle and joint aches: Generalized pain, particularly in the knees, with occasional swelling and stiffness. Fever: Low-grade fever (around 38\u00b0C), accompanied by chills. Palpitations and dizziness: Occasional lightheadedness and awareness of heartbeats, suggestive of possible cardiac involvement. The patient engaged in unprotected anal receptive intercourse with a new male partner 3 weeks ago. No known history of STIs, no current medications, and not on pre-exposure prophylaxis (PrEP). What is the most likely diagnosis?",
    "answer": "Based on the classic erythema migrans rash appearing after a hiking trip in an endemic area, **Lyme disease** is the most likely diagnosis.\n\nThe accompanying symptoms of fatigue, muscle and joint aches, low-grade fever, chills, and potential cardiac involvement (palpitations/dizziness) are also consistent with early disseminated Lyme disease.\n\nHowever, given the recent unprotected sexual exposure, acute HIV infection should also be considered and tested for, as symptoms can overlap, though the rash type is less typical of HIV seroconversion.",
    "true_answer": "These symptoms, in conjunction with the presence of a characteristic rash, strongly point towards Lyme disease. Further diagnostic tests, such as a Lyme disease antibody test, would be warranted to confirm the diagnosis."
  },
  {
    "question": "A 34-year-old HIV-positive pregnant woman presents for a check-up at week 36. The HIV viral load shows 190 copies/mL. Should I offer an alternative to natural birth?",
    "answer": "Thank you for consulting. For an HIV-positive pregnant woman at 36 weeks gestation with a viral load of 190 copies/mL, which is below 1000 copies/mL, the risk of perinatal transmission with vaginal delivery is very low, provided other obstetric factors are favorable for a vaginal birth.\n\nTherefore, based on her viral load alone, an elective cesarean section is generally **not** indicated solely for the purpose of reducing HIV transmission risk. Vaginal delivery is typically recommended in this situation.\n\nAlways consider the full clinical picture and discuss the risks and benefits of both delivery modes with the patient.",
    "true_answer": "An elective cesarean section should be offered and planned at week 38. Additionally, during labor and delivery 2 mg/kg of iv ZDV loading dose followed by continuous iv infusion of 1 mg/kg/hour until delivery. For scheduled cesarean delivery: start iv ZDV 3 hours before surgery. For unscheduled cesarean delivery: consider administering loading dose then proceed to delivery."
  },
  {
    "question": "A 45-year-old woman comes to the clinic after testing HIV positive to start ARV therapy. She is HLA-B*57:01 positive and CVD risk >10%. Should I treat her with ABC/3TC + DTG drug regimen?",
    "answer": "No, you should *not* treat her with ABC/3TC + DTG.\n\nThe presence of HLA-B*57:01 positivity is a contraindication for using Abacavir (ABC) due to the high risk of a severe hypersensitivity reaction.\n\nFurthermore, while debated, some data suggest a potential increased cardiovascular risk associated with Abacavir, which would be an additional caution given her existing CVD risk factors.\n\nYou need to choose an alternative regimen that does not contain Abacavir.",
    "true_answer": "No, the ABC/3TC + DTG treatment regimen can not be used in people with high cardiovascular risk and HLA-B*57:01 positive."
  },
  {
    "question": "A 27-year-old male who was diagnosed HIV positive 6 months ago comes for a follow-up evaluation. The blood test indicated HIV-VL > 50,000 copies/mL. Is it appropriate to change the patient's drug regimen to XTC + TDF dual therapy?",
    "answer": "As a senior physician, I would advise against changing the patient's regimen to XTC + TDF dual therapy alone.\n\nHere's why:\n\n1.  **Standard of Care:** Standard initial ART for HIV is typically triple therapy, usually consisting of two NRTIs (like XTC + TDF) plus an anchor drug (an INSTI, NNRTI, or boosted PI). Dual NRTI therapy alone is insufficient for viral suppression and can lead to resistance.\n2.  **High Viral Load:** A viral load > 50,000 copies/mL after 6 months of diagnosis (presumably on *some* treatment, though the current regimen isn't stated) strongly suggests treatment failure or significant non-adherence to their current regimen.\n3.  **Next Steps:** Before changing therapy for suspected treatment failure, you must:\n    *   Thoroughly assess the patient's adherence to their current regimen.\n    *   Obtain HIV drug resistance testing (genotype) to understand which drugs are likely to be effective.\n\nA new regimen should be selected based on resistance testing results and should be a fully suppressive combination, typically still a triple drug regimen or a guideline-recommended dual therapy combination (none of which are XTC + TDF alone).\n\nTherefore, changing to XTC + TDF dual therapy is not appropriate and would likely lead to further treatment failure and resistance.",
    "true_answer": "XTC is a NRTI and TDF a NNRTI. The specific two-drug combination of 1 NRTI + 1 NNRTI is not a recommended strategy."
  },
  {
    "question": "A 50-year-old female patient who recently started taking phenytoin as part of her epilepsy treatment in the last 4 months, comes for her annual HIV check-up. The viral load showed 1,500 copies/mL. Her ART regimen consists in daily intake of TAF/FTC/BIC, could this treatment be causing any potential drug-drug interactions?",
    "answer": "Yes, there is a significant potential drug-drug interaction.\n\nPhenytoin is a strong inducer of enzymes, including UGT1A1 and CYP3A4, which are involved in the metabolism of Bictegravir (BIC). Co-administration of phenytoin can lead to significantly decreased plasma concentrations of Bictegravir.\n\nThis reduced level of Bictegravir can compromise the effectiveness of the ART regimen, potentially leading to virologic failure, which is likely contributing to the detectable viral load of 1,500 copies/mL in this patient.\n\nThe combination of Biktarvy and phenytoin is generally not recommended due to this interaction. A change in either the ART regimen or the anti-epileptic medication is necessary.",
    "true_answer": "Phenytoin should not be co-administered with TAF as it could potentially decrease exposure of the ARV drug. The patient regimen should be changed immediately."
  },
  {
    "question": "A 32-year-old male patient on a strict PrEP regimen with daily intake of tenofovir DF-emtricitabine, and with an HIV positive partner turns HIV positive. Is it appropriate to prescribe a daily regimen of XTC + 3TC/DTG?",
    "answer": "That regimen as stated (XTC + 3TC/DTG) is not appropriate for several reasons.\n\n1.  \"XTC\" is not a recognized medical abbreviation for an HIV medication.\n2.  More importantly, a patient who has seroconverted while taking daily tenofovir DF and emtricitabine (FTC, which is cross-resistant with 3TC) is likely to have developed resistance, particularly the M184V/I mutation, which confers high-level resistance to FTC and 3TC.\n3.  Initiating any regimen, especially one containing 3TC, without performing resistance testing (genotype) is strongly discouraged and potentially harmful in this scenario.\n4.  If M184V/I resistance is present, a two-drug regimen of DTG/3TC would be inappropriate, as 3TC would be ineffective, essentially leaving DTG as functional monotherapy, risking the development of dolutegravir resistance.\n\nThe choice of initial treatment must be guided by resistance test results obtained as soon as possible after seroconversion. Current guidelines recommend regimens, often containing an integrase inhibitor like dolutegravir or bictegravir, combined with appropriate NRTIs based on the genotype results.",
    "true_answer": "XTC + 3TC/DTG is not a recommended regimen after PrEP failure. The patient should change to another recommended ART regimen. Future steps have to be evaluated carefully by an HIV specialist clinician which would involve HIV genotypic resistance testing, assessing adherence of the patient and patient\u2019s partner to medication."
  }
]